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Management of BCG Failures in Non-Muscle-Invasive Bladder 
Cancer
Kyung Seok Han, Sung Joon Hong
From the Department of Urology and Urological Science Institute, Yonsei Uni-
versity College of Medicine, Seoul, Korea
Purpose: Bacillus Calmette-Guérin (BCG) intravesical therapy is the stan-
dard treatment in high-risk patients with non-muscle-invasive bladder 
cancer, but a significant number of patients experience recurrence after 
BCG therapy. Although several treatment options are available for re-
currence after BCG therapy, the optimal treatment strategy is still 
controversial. We reviewed current and promising treatment options after 
BCG failure.
Materials and Methods: A search of published literature using PubMed 
and meeting abstracts was performed.
Results: BCG failures are further subdefined as BCG refractory, BCG 
resistant, BCG relapsing, and BCG intolerance. Several predictors for BCG 
response have been studied, but prediction or stratification before therapy 
seems to be difficult in clinical practice. Novel biomarkers associated with 
immunologic mechanisms appear to be promising to predict BCG failure. 
Radical cystectomy is the standard treatment for BCG-refractory disease, 
but the timing of cystectomy is controversial. BCG maintenance or com-
bination with interferon-α is a promising therapy for BCG resistance or 
relapse. Some salvage therapies or device-assisted instillations have been 
also promising, but the efficacy and safety of these novel therapies should 
be confirmed by large prospective studies before their clinical use in BCG 
failure.
Conclusions: Patients with BCG failure are not a homogeneous group and 
need to be stratified. Radical cystectomy should be performed without 
delay in patients with BCG-refractory status, but salvage intravesical 
therapies may be an alternative in cases without true refractory status. 
Although BCG and interferon intravesical therapy is promising, more 
efficient salvage therapy after BCG failure is required. (Korean J Urol 
2009;50:1037-1047)
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INTRODUCTION
　Since bacillus Calmette-Guérin (BCG) was first used in 
humans in 1921, its main use has been for vaccination against 
tuberculosis [1]. However, BCG has also been used in the 
immunotherapy of cancer or chronic inflammation. Until now, 
BCG was the most frequently used immunotherapeutic treat-
ment. Morales et al. investigated a new form of application for 
BCG in 1976 [2]. They developed a schedule for the effective 
adjuvant intravesical treatment of non-muscle-invasive bladder 
cancer (NMIBC) after transurethral resection (TUR) with BCG. 
Since the late 1980s, evidence has become available that 
instillation of BCG into the bladder is an effective form of 
immunotherapy in NMIBC.
　Recent meta-analyses have confirmed that BCG after TUR 
is superior to TUR alone or to TUR and chemotherapy in 
preventing recurrence [3-5]. To date, BCG intravesical therapy 
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Table 1. Subtypes of BCG failure (proposed by the first international consultation on bladder tumors)
Types Definitions
BCG-refractory
BCG-resistant
BCG-relapsing
BCG-intolerent
Failure to achieve disease-free state by 6 months after initial BCG therapy with either maintenance 
or retreatment at 3 months due to either persistent or rapidly recurring disease. Also includes any 
progression in stage, grade, or disease extent by 3 months after first cycle of BCG
Recurrence or persistence at 3 months after the induction cycle but of lesser degree, stage, or grade 
which is no longer present at 6 months from BCG retreatment and/or TUR
Recurrence of disease after achieving a disease-free status by 6 months. Relapse is further defined by 
time of recurrence:
Early: within 12 months
Intermediate: 12-24 months
Late: ＞24 months 
Caution: relapsing disease while on active maintenance (within 3 months) may qualify as BCG refractory
Disease recurrence after a less than adequate course of therapy is applied due to a serious adverse event 
or symptomatic intolerance that mandates discontinuation of further BCG.
BCG: bacillus Calmette-Guérin, TUR: transurethral resection
is the standard treatment in high-risk patients with NMIBC and 
in patients with carcinoma in situ (CIS) [6-8]. However, 
although BCG is the most effective therapy for preventing 
recurrence and progression in NMIBC, a significant number of 
patients do experience recurrence and progression after BCG 
therapy. The treatment fails in 30-40% of patients, and 30-40% 
of those who initially responded relapse. This status has been 
generally called “BCG failure” [9].
　Several treatment options for recurrence after BCG therapy 
are available. Radical cystectomy or salvage intravesical 
therapy can be selectively chosen as the treatment of BCG 
failure according to disease status. Currently, several agents or 
treatment protocols are now being investigated for overcoming 
BCG failure. However, the optimal treatment strategy of BCG 
failure is still controversial. Therefore, in this article, we review 
current and promising treatment options after BCG failure.
DEFINITION OF BCG FAILURE
　Although BCG failure is a generally used term for recurrence 
after BCG therapy in bladder cancer, its definition is not clear. 
Clear definitions of BCG failure are needed in both the clinical 
and the research setting. By strict definition, any recurrence of 
tumor after BCG therapy can be termed a BCG failure, but not 
all failures under this definition have a similar prognosis [10]. 
Some series have defined BCG failure after a single induction 
course of BCG, and others after two courses [11-13]. In 
addition, most studies have included all patients who received 
one or more courses of BCG. Investigators have often com-
bined patients with persistent disease and patients with recur-
rent disease after an initial response, and a few studies have 
combined patients who were nonresponders to BCG and pa-
tients who could not complete BCG therapy because of toxicity 
[14]. These differences in definition might affect the results of 
the studies of BCG failure and account for the wide disparity 
in response rates. In clinical practice, vague definitions make 
it more difficult for clinicians to decide when to abandon BCG 
and to start other treatment options.
　Recently, efforts have been made to clarify the definition of 
BCG failure. Herr and Dalbagni suggested definitions to clarify 
refractory and resistant disease [15]. They reported that the 
presence of a tumor at the 6-month evaluation after initial BCG 
was predictive of subsequent tumor recurrence, whereas tumor 
presence at 3 months was not predictive. These concepts were 
further stratified into BCG-refractory, BCG-resistant, BCG- 
relapsing, and BCG-intolerance at the First International Con-
sensus Meeting in 2005 (Table 1) [16]. This subclassification 
allows clinicians to understand current disease status after 
adjuvant BCG therapy and can aid clinical decisions about 
when to abandon BCG and what to choose as the proper 
treatment option after BCG. The International Bladder Cancer 
Group emphasized the importance of distinguishing recurrences 
from treatment failures and also acknowledged that defining the 
type of BCG failure may be helpful in deciding whether 
conservative management or cystectomy is required [17]. 
However, currently updated guidelines of NMIBC still have no 
consensus about the definition of BCG failure. Much more 
evidence clinically supporting the subclassifications of the 
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definition will be needed for general consensus.
PREDICTION OF BCG FAILURE
　Several studies have investigated the factors predictive of the 
BCG response in NMIBC. Although some studies have 
reported the potential prediction of recurrence or progression 
after BCG, after more than two decades of study, no 
independent prognostic factor for remission or relapse after 
BCG therapy appears to have been identified [18]. However, 
recent studies have reported novel predictive factors.
1. Demographic predictors
　Recent multivariate analyses based on large, multicenter 
bladder cancer patient cohorts of greater than 1,000 patients 
have suggested some independent predictors for recurrence and 
progression after BCG induction and short-term maintenance 
treatment [19]. Analysis from a Spanish group with 1,062 
patients with NMIBC suggested that female gender, history of 
recurrence, multiplicity, and presence of CIS are predictors for 
recurrence, and age, history of recurrence, high grade, T1 stage, 
and recurrence at initial cystoscopy are predictors for pro-
gression [19].
2. T1 substaging
　Microstaging of T1 tumors may help to select tumors with 
a higher risk of progression. Several reports in the past 10 years 
have demonstrated a worse prognosis for T1 tumors with deep 
lamina propria invasion, with progression rates ranging from 
29% to 55% [20-22]. Subgrouping of T1 tumors uses the 
muscularis mucosa as a landmark of microstaging. According 
to the muscularis mucosa, T1 tumors are classified into T1a 
when the tumor involves the subepithelial connective tissue 
superficial to the muscularis mucosa, T1b when it goes into the 
level of the muscularis mucosa, and T1c when it goes beyond 
the muscularis mucosa [21]. In a study of 49 patients with T1 
bladder cancer, Kondylis et al showed that substaging of T1 
tumors did not affect response to BCG regarding recurrence or 
progression [20]. In contrast, Orsola et al reported that patients 
with high-grade T1 bladder cancer invading the muscularis 
mucosa (T1b) had a seven times higher risk of a positive repeat 
TUR at 3 months after the initial TUR and BCG therapy if 
the initial tumor was greater than 3 cm and a five-fold 
increased risk if associated with CIS [21,22]. However, this 
result has not been confirmed in a prospective study.
3. Tumor markers
　Tumor marker expression has been investigated as a pre-
dictive factor for recurrence or progression in several cancers 
with various stages and has also been investigated in bladder 
cancer treated with BCG, but the results have been inconsistent. 
Some investigators reported that P53 and Ki-67 protein over-
expression are independent predictors for recurrence in NMIBC 
treated with BCG [23,24], but others have reported no 
significant associations [25-28]. The results for ezrin protein 
expression were similarly inconsistent [24,27,29]. Recently, 
pRb was proposed as a predictive factor of nonresponse and 
recurrence after BCG plus IFN-α [28]. However, because 
these markers have not been confirmed by a prospective study, 
debate about these issues remains.
4. Cytokines
　Various cytokines or cytokine-related parameters have been 
investigated as a predictive or prognostic factor in NMIBC 
treated with BCG. These include cytokine gene polymorphisms, 
tumor necrosis factor-alpha gene, antigen-presenting molecules 
and chemokines, T helper 1 and 2 lymphocyte urinary cytokine 
profiles, and urinary interleukin-8 [30-35]. Some reports have 
shown promising results for cytokines as the predictive factor 
of BCG response or prognosis, but despite decades of 
investigation, there are still no molecular markers that predict 
response to BCG.
5. Immune cells
　Tumor cells are surrounded by infiltrating inflammatory 
cells, which communicate via a complex network of inter-
cellular signaling pathways. Tumor-associated macrophages 
(TAMs) can regulate the growth of various cancers either 
positively or negatively. Takayama et al investigated the 
prognostic role of TAMs in CIS after BCG by measuring the 
cancer cell-to-lamina propria TAM ratio [36]. In that study, 
higher cancer cell TAM counts and higher cancer cell-to-lamina 
propria TAM ratio were independent prognostic factors for 
recurrence after BCG. Ayari et al performed a similar study 
with TAMs and tumor-infiltrating dendritic cells (TIDCs) [37]. 
They demonstrated that a high level of infiltration by CD83 
(＋) TIDCs or CD68 (＋) TAMs does not respond as well to 
BCG immunotherapy. These two studies emphasize the 
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Fig. 1. Cancer-free survival rates for bacillus Calmette-Guérin 
(BCG)-naïve and BCG-failure patients with different failure 
patterns ([39] Gallagher, et al. Urology 2008;71:297-301. 
reproduced with permission of the publisher, Elsevier).
prognostic significance of tumor-infiltrating immune cells for 
the response to BCG, but large, prospective studies are required 
to confirm these findings.
TREATMENT OPTIONS AFTER BCG FAILURE
　Patients with T1G3 bladder cancer have a markedly varied 
potential for tumor progression, whereas more than a third do 
not experience recurrence or progression. Radical cystectomy 
may be the best treatment in high-risk patients but is an 
overtreatment in patients who will have no recurrence or 
progression. Therefore, patient selection might be important to 
manage patients who fail BCG therapy. Several salvage 
therapies after failure of BCG have been studied, and some 
therapies have shown promising results as second-line intra-
vesical therapy after BCG.
1. Radical cystectomy
　Currently, radical cystectomy with pelvic lymph node 
dissection is the standard treatment for patients who have failed 
BCG. This treatment provides a good 5-year survival rate of 
70-90%, and orthotopic neobladder reconstruction has been 
established as the standard procedure that provides good quality 
of life [10,38]. However, cystectomy yields a 2-3% mortality 
rate and 20-30% complication rates. Some patients who un-
dergo cystectomy may suffer when adjusting to postoperative 
changes in their quality of life. Early cystectomy would be an 
overtreatment, even in high-risk patients, because more than 
one third of T1G3 bladder cancer patients do not experience 
recurrence or progression.
　The most debatable issue is when cystectomy should be 
performed [38]. No prospective randomized trial has evaluated 
the optimal timing of cystectomy in these patients. The timing 
of cystectomy is an important prognostic factor. Several studies 
have emphasized the risk of delayed cystectomy in high-risk 
NMIBC. One study of BCG plus interferon-α (IFN-α) in 
1,106 NMIBC patients suggested that the timing of BCG failure 
is a significant predictor for subsequent recurrence [39]. In that 
study, patients with disease recurrence more than 1 year after 
BCG treatment and who were treated with low-dose BCG plus 
interferon-alpha had response rates similar to those of BCG- 
naïve patients treated with regular-dose BCG plus interferon 
(Fig. 1) [39]. From this result, the authors suggested that pa-
tients with BCG failure more than 1 year after BCG might 
benefit from another trial with intravesical immunotherapy, 
whereas patients with recurrence within 1 year of BCG should 
be considered for either cystectomy or alternative intravesical 
therapies. In addition, a recent historical comparative study 
suggested that a paradigm shift has occurred because patients 
are increasingly offered radical cystectomy before disease 
progression to muscle invasion [40]. As a result, the disease- 
specific death of the contemporary cohort in which preemptive 
radical cystectomy was performed was less than that of the 
historical cohort in which the bladder was preserved until 
progression to muscle invasion [40]. Another study demon-
strated that patients who underwent surgery less than 2 years 
after initial transurethral resection of bladder tumor (TURBT) 
for high-risk NMIBC had a significantly improved survival 
compared with similar patients who had surgery after 2 years 
[41-43]. Herr et al have suggested that tumor response at 6 
months was the most important factor for predicting ultimate 
failure and progression [42]. Therefore, it is recommended that 
cystectomy should not be delayed in high-risk patients beyond 
6 months (two courses of BCG) [38].
　Radical cystectomy allows us to overcome the clinical 
limitation of under-staging and thus can help to direct appro-
priate therapy for more advanced tumors earlier in the time 
course. Proponents of early cystectomy point out that a signi-
ficant proportion of patients who undergo delayed cystectomy 
subsequently die of the disease, and a significant proportion of 
patients who progress during conservative management had 
resectable disease at the time of cystectomy, which dramatically 
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increased the risk of death [38]. The proponents of early 
cystectomy also note that conservative management mandates 
life-long surveillance that includes routine cystoscopy, as well 
as radiographic evaluation and adjuvant therapies, as dictated 
by recurrences [38]. However, no reliable data have been 
published regarding the cost savings of early cystectomy versus 
conservative management at this time. Furthermore, the issue 
of the quality of life of patients undergoing long-term sur-
veillance, in particular the effects of the anxiety associated with 
this option, compared with the postoperative quality of life 
challenges associated with cystectomy, has not been adequately 
studied to date.
2. Salvage intravesical immunotherapy
　1) Repeat BCG or maintenance: Although each additional 
course of BCG carries a 7% actuarial risk of progression after 
BCG failure, as many as 40-80% of patients who appear to 
have failed the initial BCG therapy show a durable response 
after a second course of BCG [44,45]. Therefore, patients 
should not be considered a true failure if they have received 
only one course of BCG. Another course of BCG can be 
applied to these patients, whereas patients who have evidence 
of disease after two courses are unlikely to respond to addi-
tional BCG therapy and are at risk for progression of disease 
[10]. These patients, who were classified as BCG refractory, 
are “true BCG failures” and treatment options other than BCG 
should be considered. Patients who delay definitive therapy by 
receiving two doses of initiation therapy or an alternative 
treatment for BCG-refractory disease may be at increased risk 
for progression with a proportionate decrease in long-term 
survival and, therefore, early cystectomy is the best choice of 
treatment in these patients [10,17,38,41].
　Although the merits of a maintenance course have been 
debated in the past, BCG maintenance is highly recommended 
as the standard adjuvant treatment in high-risk NMIBC [10]. 
With increasing data showing its benefits, a maintenance course 
of BCG at 3 months is currently accepted. Meta-analyses 
showed that induction BCG followed by maintenance BCG 
decreases recurrence in high-risk patients, although most 
patients did not complete the entire course to 36 months 
[46,47]. However, Herr pointed to the bias included in these 
meta-analyses, which exaggerated the efficacy of BCG main-
tenance, and insisted that critical analysis of the evidence does 
not support the liberal use of maintenance BCG as currently 
practiced and recommended [48]. Herr suggested that main-
tenance BCG does not appear superior to initial BCG treatment 
in preventing or delaying tumor progression and that prolonged 
BCG treatment adds toxicity [48]. However, the decision for 
maintenance of BCG after BCG failure must depend on disease 
status. BCG maintenance is not optimal in patients with 
BCG-refractory status, but is recommended as the adjuvant 
treatment after an additional BCG induction course in patients 
with BCG resistance or relapse, or even in patients with 
BCG-intolerance.
　2) BCG plus interferon-α: Interest in interferon as an 
intravesical agent against bladder cancer developed in the 1980s 
[41]. Results of early prospective series with interferon were 
disappointing. The long-term success rate of IFN-α mono-
therapy of BCG failures is generally less than 15% [49]. 
Furthermore, one study of IFN-α found it to be no better than 
water placebo at 43 months of follow-up, which suggests that 
it has no role in recurrent stage T1 disease [50]. However, over 
the subsequent decade, sufficient experience with both agents 
accumulated to suggest using them together as salvage therapy 
in patients with recurrence after intravesical BCG.
　A large, national, multicenter phase II trial assessed the 
efficacy of the combination of BCG and interferon [51]. This 
trial showed that this combination therapy is well tolerated and 
appears to prolong the disease-free interval in previous BCG- 
failure patients. With a median follow-up of 24 months, 45% 
of BCG failures remained recurrence-free compared with 59% 
in the BCG-naïve group treated with a normal dose of BCG 
(Fig. 2). Although the definition of BCG failure was quite 
liberal and included some BCG-intolerant patients, this trial 
showed that the combination of BCG and IFN seems a 
promising second-line immunotherapy regimen after BCG 
failures, but the results of this phase II trial should be 
confirmed [10].
3. Salvage intravesical chemotherapy
　Several intravesical drugs have been investigated in high-risk 
patients who failed BCG. Conventional intravesical chemo-
therapeutic agents have been investigated in a few studies but 
did not show satisfactory efficacy. Platinum derivatives have 
been tried but were generally too irritating and associated with 
occasional fatal anaphylaxis [52]. Recently, two newer cyto-
toxic chemotherapeutic drugs, gemcitabine and docetaxel, with 
known systemic activity against advanced bladder cancer have 
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Fig. 2. Kaplan-Meier recurrence rates in patients receiving intra-
vesical bacillus Calmette-Guérin (BCG) and interferon (IFN) 
characterized by whether they had never received BCG (BCG-N) 
or had tumor recurrence after prior BCG (BCG-F). ([51] Joudi, et 
al. Urol Oncol 2006;24:344-8. reproduced with permission of the 
publisher, Elsevier)
been tried in the intravesical route.
　1) Mitomycin C: Only a few attempts have been made to 
treat BCG failures with conventional intravesical chemotherapy. 
The Swedish-Norwegian Bladder Cancer Group compared 
mitomycin C (MMC) and BCG in NMIBC patients, and treat-
ment failures were allowed to cross over to the other treatment 
[53]. Twenty-one patients with BCG failure changed to MMC 
therapy, but only four remained recurrence free with a median 
follow-up period of 64 months. Conventional intravesical che-
motherapy generally appears to not be effective in BCG 
tolerance.
　2) Valrubicin: Valrubicin, a new anthracycline derivative, is 
the only drug approved by the US Federal Drug Administration 
(FDA) for patients with CIS failing BCG therapy [54]. The 
FDA approval of this agent was based on a small phase II trial 
with 90 patients. After a 1-year follow-up, only 21% showed 
a complete response and only 8% were disease free at the 
2-year follow-up [55]. A marker lesion study in refractory 
patients confirmed some potential of valrubicin, with 18 of 39 
(46%) patients free of disease after 3 months. However, 
valrubicin was withdrawn from the market in 2002 because of 
impurities in its original formulation and is therefore not 
currently used.
　3) Gemcitabine: Gemcitabine is a novel deoxycytidine 
analogue with a broad spectrum of antitumor activity [41]. To 
date, gemcitabine is one of the standard chemotherapeutical 
agents in systemic therapy for advanced bladder cancer and also 
has been studied for its potential for intravesical use for 
NMIBC. Intravesical gemcitabine has been generally well 
tolerated with minimal induction of cystitis and little systemic 
absorption. The exception has been in patients who received 
previous multiple treatments, where gemcitabine intolerance 
was seen in 8 of 64 (13%) patients, necessitating withdrawal 
[56].
　The first phase I study in 18 patients refractory to BCG and 
treated with gemcitabine on refusing cystectomy reported that 
intravesical gemcitabine therapy given twice weekly was asso-
ciated with minimal bladder irritation and tolerable myelo-
suppression [57]. Activity against marker lesions and primary 
and previous refractory tumors has been demonstrated in 
multiple phase I and phase II trials with gemcitabine, and the 
marker lesion response varies, with the highest response rate 
reported of 56% [57-61]. In a phase II trial of gemcitabine for 
BCG refractory patients, Bartoletti et al. reported that when 
2,000 mg gemcitabine in 50 ml was used, 18 of 24 (75%) 
intermediate-risk and 7 of 16 (43.7%) high-risk BCG-refractory 
patients remained recurrence free [59]. Also, Dalbagni et al 
conducted a phase II study using a more intensive, twice- 
weekly administration in 30 BCG-refractory patients and 
reported that with a median follow-up of 19 months, 15 of 30 
(50%) had an initial complete response [62]. These studies have 
confirmed the potential of gemcitabine in these patients. 
However, in the largest most dose-intensive regimen with the 
longest follow-up, the 1-year complete response rate was only 
21%, suggesting that single-agent gemcitabine will not likely 
meet its role as a universal salvage drug [14].
　4) Docetaxel: Docetaxel is a chemotherapeutic agent that has 
recently been investigated for intravesical therapy. A phase I 
trial showed that docetaxel is safe for intravesical therapy in 
patients with BCG-refractory NMIBC, with no systemic 
absorption and limited toxicity. Of the 18 patients, 56% had 
no evidence of disease at the cystoscopy and biopsy after 
treatment, and 22% remained disease free during the median 
32.5 months of follow-up [63]. There has been no phase II trial, 
but recently, an extended report for intravesical docetaxel was 
made by the same group [64]. In that study, monthly main-
tenance therapy with intravesical docetaxel was performed in 
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13 patients with BCG refractory Ta, T1, or CIS to overcome 
the low durability in the previous study. With a median 13 
months of follow-up, 10 of 13 patients had a complete response 
after induction, and 6 have remained disease-free. All 10 
responders completed at least three instillations of maintenance, 
of whom 6 have remained recurrence-free. In summary, intra-
vesical docetaxel is tolerable and has shown promising results 
in patients with BCG failures, but a phase II study should be 
performed to confirm its efficacy.
　5) Combination therapy: Although multi-agent chemo-
therapy has become universal for almost all cases of systemic 
chemotherapy, previous attempts to use combined or alternating 
older chemotherapy drugs, such as adriamycin and mitomycin, 
intravesically were frustrated by severe cystitis despite some 
evidence of enhanced activity [14]. However, combinations of 
drugs in which one or both are non-vesicants may be better 
received [14]. One such combination of immediate sequential 
gemcitabine followed by mitomycin reported a near 50% 
recurrence-free rate in 27 BCG refractory patients at 18 months 
compared with 20% for gemcitabine alone in 12 similar 
patients [65]. Further prospective studies with combinations of 
other intravesical chemotherapeutic agents including gemci-
tabine and docetaxel deserve to be carried out.
4. Device-Assisted instillations
　Although intravesical chemotherapy is not a standard 
treatment option in BCG failures, intravesical chemotherapy 
combined with an energy source might be better. Combining 
intravesical chemotherapy with an energy source can improve 
drug delivery. Device-assisted instillations using novel devices 
such as electromotive drug administration (EDMA), thermo-
therapy, and photodynamic therapy have also been investigated 
and have shown favorable results but are still in phase I trials. 
　1) MMC and EMDA: The feasibility and safety of both 
techniques were compared and tested as four weekly ablative 
sessions before TUR in 15 patients [66]. Di Stasi et al and col-
leagues conducted a randomized controlled trial of sequential 
electromotive MMC in high-risk patients [67]. In that study, 
212 patients with pT1 bladder cancer were randomly assigned 
to conventional BCG induction cycle or to BCG followed by 
electromotive MMC once per week for three cycles followed 
by maintenance treatment. Patients assigned sequential BCG 
and electromotive MMC had a higher disease-free interval and 
lower recurrence than did patients assigned BCG alone [67]. 
This combination of chemotherapy and EMDA appears to be 
promising in high-risk patients but has not been investigated 
in BCG failure yet. The BCG failure group would be the next 
reasonable study population for this combination therapy.
　2) Thermochemotherapy: The combination of intravesical 
hyperthermia and MMC has also been studied recently. This 
treatment combines heating of the bladder wall to a temperature 
of around 42oC with a cooled solution of MMC. Several studies 
have shown that thermochemotherapy and MMC is superior to 
MMC alone and can be used both to prevent recurrences and 
as ablative treatment [54,68]. Thermochemotherapy has also 
been reported to be successful in BCG failures [69,70]. In a 
study of CIS patients, most of whom had failed BCG, treated 
with MMC combined with hyperthermia, Alfred et al reported 
a response rate of 92% at the initial cystoscopy with biopsies 
3 months after treatment, and 51% of patients remained 
recurrence-free at a median follow-up of 27 months. However, 
longer follow-up and more results are required to indicate the 
value of thermochemotherapy in patients with BCG failures 
[70].
　3) Photodynamic therapy: Photodynamic therapy (PDT) is 
a minimally invasive therapeutic modality approved for the 
treatment of several cancers [71]. PDT involves the admini-
stration of a tumor-localizing photosensitizer followed by its 
activation with light of a specific wavelength. In the presence 
of tissue oxygen, the photoactive sensitizer triggers a series of 
photochemical and photobiological processes that may lead to 
direct cancer cell damage, tumor microvascular occlusion, and 
host immune response [72]. Waidelich et al performed PDT 
after the oral administration of 5-aminolevulinic acid (5-ALA) 
in 24 patients with BCG-refractory bladder cancer [73]. In that 
study, at a median follow-up of 36 months, 3 of 5 patients with 
CIS and 4 of 19 with papillary tumors were recurrence free. 
Tumor progression was stopped in 20 of 24 cases. Hypotension 
and tachycardia occurred in 19 and 10 patients, respectively, 
immediately after the oral administration of 5-ALA. Berger et 
al reported the results of PDT in 31 patients including 10 BCG 
failure patients [74]. In the 10 BCG failure patients treated by 
PDT, 40% were free of recurrence after a mean follow-up of 
11.8 months. These initial clinical results suggest that PDT with 
oral 5-ALA may be effective in BCG failure. However, 
systemic side effects such as hemodynamic instability after oral 
ALA, particularly in patients with cardiovascular co-morbidity, 
should be overcome.
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5. Chemoradiation therapy
　Recently, the Harvard Radiation Oncology Group reported 
their experiences of bladder-sparing trimodality therapy in 
high-risk NMIBC patients who have progressed to muscle- 
invasive disease [75]. The bladder-intact survival rate at 3, 5, 
and 7 years was 61%, 54%, and 54%, respectively. Although 
this was a small retrospective study, their favorable results 
suggest that concurrent chemoradiation therapy can be used in 
the management of high-risk T1 bladder cancer. However, there 
has been no study of chemoradiation therapy in BCG failure 
patients.
CONCLUSIONS
　Patients with BCG failures are not a homogeneous group and 
need to be stratified through the assessment of a potential 
response for further BCG and future progression risk. Novel 
biomarkers or cells associated with immunologic mechanisms 
appear to be promising to predict BCG failure, but there is still 
a long way to go. Radical cystectomy should be performed 
without delay in patients with BCG-refractory status, but 
salvage intravesical therapies may be an alternative option in 
patients without true refractory status. Although some salvage 
intravesical therapies including BCG plus IFN-α are promising 
and are being investigated, more efficient and powerful 
treatments appear to be required in the management of BCG 
failures.
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